SOM Biotech at International Symposium on “Rare diseases and Big Data”
Dr. Ferruccio Palazzesi, SOM Biotech Senior Computational Chemist, attended the International Symposium on “Rare diseases […]
Continue ReadingSOM Biotech releases a new version of its proprietary drug repurposing process
Using the latest modular workflow technologies, SOM Biotech has released a new version of his […]
Continue ReadingNippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)
SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension […]
Continue ReadingSOM Biotech at 2017 ASEBIO Investor Day
SOM Biotech was one of the presenting companies at 2017 ASEBIO Investor Day. ASEBIO Investor Day is […]
Continue ReadingSOM Biotech invited at Chinese-Swiss Health Collaborations Forum
SOM Biotech was one of the companies invited to the Private Chinese-Swiss Investor Collaborations Forum […]
Continue ReadingII Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne
La Compañía SOM Biotech estuvo presente en el II Workshop sobre Transferencia del Conocimiento Científico en la […]
Continue ReadingSOM Biotech licenses its first product and expands to the United States
The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system […]
Continue ReadingSOM Biotech at the 2017 New York Venture Summit
SOM Biotech was selected to present at the 2017 New York Venture Summit in front […]
Continue Reading21st Summer School of the University of Barcelona
Dr. Raúl Insa, SOM Biotech CEO, was invited to the 21st Summer School of the University […]
Continue Reading9th Summer School on Medicines
Dr. Raúl Insa, SOM Biotech CEO, was the invited speaker at Closing Session of 9th […]
Continue Reading